Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Capital Expenditures (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Capital Expenditures for 6 consecutive years, with -$746000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 155.8% to -$746000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12000.0 through Dec 2025, down 99.12% year-over-year, with the annual reading at $12000.0 for FY2025, 99.12% down from the prior year.
  • Capital Expenditures hit -$746000.0 in Q4 2025 for Rapid Micro Biosystems, down from $683000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.8 million in Q2 2022 to a low of -$770000.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $588850.0 across 5 years, with a median of $396000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: surged 2341.54% in 2022 and later crashed 243.26% in 2024.
  • Year by year, Capital Expenditures stood at $2.4 million in 2021, then tumbled by 65.64% to $811000.0 in 2022, then plummeted by 70.53% to $239000.0 in 2023, then surged by 459.41% to $1.3 million in 2024, then tumbled by 155.8% to -$746000.0 in 2025.
  • Business Quant data shows Capital Expenditures for RPID at -$746000.0 in Q4 2025, $683000.0 in Q3 2025, and -$31000.0 in Q2 2025.